Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia.


Change log
Authors
Parthymos, Ioannis 
Kostapanos, Michael S  ORCID logo  https://orcid.org/0000-0002-7513-5319
Liamis, George 
Abstract

Hypertriglyceridemia has been identified as a risk factor for cardiovascular disease and acute pancreatitis. To date, there are only few drug classes targeting triglyceride levels such as fibrates and ω-3 fatty acids. These agents are at times insufficient to address very high triglycerides and the residual cardiovascular risk in patients with mixed dyslipidemia. To address this unmet clinical need, novel triglyceride-lowering agents have been in different phases of early clinical development. In this review, the latest and experimental therapies for the management of hypertriglyceridemia are presented. Specifically, ongoing trials evaluating novel apolipoprotein C-III inhibitors, ω-3 fatty acids, as well as fibroblast growth 21 analogues are discussed.

Description
Keywords
triglycerides, apolipoprotein C-III, lipoprotein lipase, ω-3 fatty acids, volanesorsen, fibroblast growth 21 factor
Journal Title
J Cardiovasc Dev Dis
Conference Name
Journal ISSN
2308-3425
2308-3425
Volume Title
9
Publisher
MDPI AG